enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the...
TW's Take: very positive results sets the stage for approval if the efficacy data comes through as expected. We'll see that data in the...
NVNO in the News Today…Premium Subscriber Update
enVVeno (NVNO) put out a hat trick of press releases today. The news ranged from getting $28 million in a private placement to fundamental...
enVVeno Medical Announces New Expedited Development Plan for the enVVe® Transcatheter Based Replacement Venous...
TW's Take: this product has multi-billion dollar potential and it's great to see the timeline moved up by 6 months. Non-surgical implantation is a...
enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial
TW's Take: company is exceeding expectations on all fronts. Great news.
– 18 VenoValve patients enrolled over the final two months of the study
– Surge...
enVVeno Medical Announces Private Placement of $28 Million
TW's Take: very positive getting top-notch investors to pay above the market. Financing risk now completely eliminated and the company is exceeding timelines on...
enVVeno Medical to Host Virtual KOL Event on July 18, 2023
TW's Take: we continue to believe this device is going to succeed and be a big deal for NVNO.
IRVINE, CA / July 14, 2023...
enVVeno Medical Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study and Announces Upcoming...
TW's Take: trial progressing well, results will come early next year which is a modest delay from the original timeline but expected in any...
enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer
TW's Take: our view on NVNO remains that the product will gain approval and substantial sales, but likely remains off investors' radar screens until...